Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting

被引:9
作者
Klok, RM
Arents, NLA
de Vries, R
Thijs, JC
Brouwers, JRBJ
Kleibeuker, JH
Postma, MJ
机构
[1] Univ Groningen, Inst Drug Explorat, Dept Social Pharm Pharmacoepidemiol & Pharmacothe, Groningen, Netherlands
[2] Univ Groningen, Med Ctr, Dept Med Microbiol, Groningen, Netherlands
[3] Bethesda Hosp, Dept Internal Med, Hoogeveen, Netherlands
[4] Univ Groningen, Med Ctr, Dept Gastroenterol, Groningen, Netherlands
关键词
dyspepsia; Helicobacter pylori; management strategies; cost-effectiveness;
D O I
10.1016/j.clinthera.2005.10.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: In western European countries, most dyspeptic patients are initially managed by their general practitioners (GPs), who use a range of strategies to manage dyspepsia. We performed an economic analysis of a Helicobacter pylori test-and-treat strategy versus a prompt endoscopy approach in a primary care setting. Methods: Data were used from the Strategy: Endoscopy versus Serology (SENSE) study, performed in The Netherlands from 1998 to 2001. Patients were randomized to a prompt endoscopy (n = 105) or test-and-treat (n = 118) group. Follow-up lasted I year. Adverse events were not recorded in the SENSE study. Health care costs were based on the total amount of dyspepsia-related drugs used, the number of dyspepsia-related GP visits, the number of diagnostic tests, and the number of dyspepsia-related referrals to specialists. The use of medical resources was calculated as standardized costs for 1999, recorded as euros. (On December 31, 1999, Euro1.00 = US $1.00.) Quality of life was measured at inclusion and 1 year later, using the RAND-36 questionnaire. To calculate quality-adjusted life-years (QALYs), we transformed the individual scores of the RAND-36 into I overall score, the Health Utilities Index Mark 2, which introduced a limitation to the study. An incremental cost-effectiveness ratio (ICER) was calculated. The 95% confidence limits were calculated using a parametric bootstrap method with angular transformation. All cost data were analyzed from a third-party payer perspective. Results: The total costs per patient were Euro511, with 0.037 QALY gained per patient, in the test-and-treat group, and Euro748, with 0.032 QALY gained per patient, in the endoscopy group (between groups, P < 0.001 and P = NS, respectively). The point estimate of the ICER indicated that the test-and-treat strategy yielded cost savings and QALYs gained. Parametric bootstrap confidence limits indicated cost savings per QALY gained in 75.7% of the bootstrap simulations. Conclusion: This analysis of data from the SENSE study suggests that the H pylori test-and-treat strategy was more cost-effective than prompt endoscopy in the initial management of dyspepsia in general practice, from the perspective of a third-party payer.
引用
收藏
页码:1647 / 1657
页数:11
相关论文
共 49 条
  • [1] Approach to treatment of dyspepsia in primary care -: A randomized trial comparing "Test-and-treat" with prompt endoscopy
    Arents, NLA
    Thijs, JC
    van Zwet, AA
    Pool, MO
    Götz, JM
    van de Werf, GT
    Reenders, K
    Sluiter, WJ
    Kleibeuker, JH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (13) : 1606 - 1612
  • [2] BHATTACHARYYA K, 1977, STAT CONCEPTS METHOD
  • [3] Briggs AH, 1996, BRIT MED J, V312, P1647
  • [4] Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age
    Briggs, AH
    Sculpher, MJ
    Logan, RPH
    Aldous, J
    Ramsay, ME
    Baron, JH
    [J]. BRITISH MEDICAL JOURNAL, 1996, 312 (7042) : 1321 - 1325
  • [5] EMPIRICAL H-2-BLOCKER THERAPY OR PROMPT ENDOSCOPY IN MANAGEMENT OF DYSPEPSIA
    BYTZER, P
    HANSEN, JM
    DEMUCKADELL, OBS
    [J]. LANCET, 1994, 343 (8901) : 811 - 816
  • [6] *CENTR MED PHARM C, 1999, PHARM COMP
  • [7] *COLL TAR GEZ, 1999, HOSP RAT LIST
  • [8] *COLL TAR GEZ, 1999, MED SPEC RAT BOOK
  • [9] Cook JR, 2000, STAT MED, V19, P2989, DOI 10.1002/1097-0258(20001115)19:21<2989::AID-SIM599>3.0.CO
  • [10] 2-G